Matinas BioPharma Holdings, Inc. — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Matinas BioPharma (market cap ~$4.5M) filed an 8-K on July 24, 2026 reporting termination of a material definitive agreement effective July 23, 2026. The filing does not disclose the identity of the counterparty, the nature of the agreement, financial terms, or reasons for termination—only that Item 1.02 was triggered.
Why this rating
Material agreement termination for a micro-cap biotech is significant absent contrary detail. Lack of disclosure limits confidence; could signal loss of revenue, partnership, or financing critical to a $4.5M company.
Extracted items
- 1.02 agreement termination
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.